Investigations on mutations in katG gene and inhA promoter region associated with isoniazid resistance in the clinical isolates of mycobacterium tuberculosis from Tehran, Iran
Isoniazid resistance in mycobacterium tuberculosis
DOI:
https://doi.org/10.22122/cdj.v12i2.795Keywords:
Mycobacterium Tuberculosis, Resistance, Isoniazid, Mutation, KatG, InhAAbstract
BACKGROUND: Isoniazid (INH) is one of the first-line drugs used for the treatment of Mycobacterium tuberculosis (Mtb). This study aimed to determine the mutations in katG and inhA promoter regions associated with INH resistance in clinical isolates of Mtb from Tehran, Iran.
METHODS: This descriptive cross-sectional study was conducted in the tuberculosis (TB) center of Tehran in 2020. 50 samples obtained from these patients were cultured on Löwenstein-Jensen medium (LJ), then, INH-resistant strains and their minimum inhibitory concentration (MIC) were determined using the proportional method. To determine the INH-resistance mutations, sequencing was performed following the amplification of both katG and inhA genes using real-time polymerase chain reaction (PCR). The genetic relationships were determined based on each strain's genetic pattern using the primers related to enterobacterial repetitive intergenic consensus PCR (ERIC-PCR), which is a proper tool used for typing Mtb strains. In this study, the phylogenetic tree was plotted using NTSYS software.
RESULTS: Five INH-resistant Mtb strains were isolated from 50 patients with TB in Tehran. All the studied resistant strains (100%) showed a mutation in codon 315 of the katG gene; none of them exhibited any mutation in the promoter. I335T mutation was observed in one INH-resistant strain (20%). The phylogenetic tree of the strains indicated seven clusters as well as 31 patterns in the strains. The strain with two mutations in 335 and 315 had MIC > 8.
CONCLUSION: KatG mutation could result in a high level of INH resistance. Therefore, routine identification of this mutation can help in determining the INH resistance, thereby preventing further propagation of these strains.
References
Kiran D, Podell BK, Chambers M, Basaraba RJ. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Semin Immunopathol. 2016; 38(2): 167-83.
Gagneux S. Ecology and evolution of Mycobacterium tuberculosis. Nat Rev Microbiol. 2018; 16(4): 202-13.
Metanat M, Sharifi-Mood B, Alavi-Naini R, Aminianfar M. The epidemiology of tuberculosis in recent years: Reviewing the status in south-eastern Iran. Zahedan J Res Med Sci. 2012; 13(9): e93704.
Gemechu A, Giday M, Worku A, Ameni G. In vitro anti-mycobacterial activity of selected medicinal plants against Mycobacterium tuberculosis and Mycobacterium bovis strains. BMC Complement Altern Med. 2013; 13: 291.
Hoagland DT, Liu J, Lee RB, Lee RE. New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Deliv Rev. 2016; 102: 55-72.
Hu YQ, Zhang S, Zhao F, Gao C, Feng LS, Lv ZS, et al. Isoniazid derivatives and their anti-tubercular activity. Eur J Med Chem. 2017; 133: 255-67.
Kandler JL, Mercante AD, Dalton TL, Ezewudo MN, Cowan LS, Burns SP, et al. Validation of novel mycobacterium tuberculosis isoniazid resistance mutations not detectable by common molecular tests. Antimicrob Agents Chemother. 2018; 62(10): e00974-18.
Wang P, Pradhan K, Zhong XB, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016; 6(5): 384-92.
Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov AS. Isoniazid-rifapentine for latent tuberculosis infection: A systematic review and meta-analysis. Am J Prev Med. 2018; 55(2): 244-52.
Flentie K, Harrison GA, Tukenmez H, Livny J, Good JAD, Sarkar S, et al. Chemical disarming of isoniazid resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2019; 116(21): 10510-7.
Nasiri MJ, Rezaei F, Zamani S, Darban-Sarokhalil D, Fooladi AA, Shojaei H, et al. Drug resistance pattern of Mycobacterium tuberculosis isolates from patients of five provinces of Iran. Asian Pac J Trop Med. 2014; 7(3): 193-6.
Marjani M, Baghaei P, Tabarsi P, Shamaei M, Mansouri D, Masjedi MR, et al. Drug resistance pattern and outcome of treatment in recurrent episodes of tuberculosis. East Mediterr Health J. 2012; 18(9): 957-61.
Nguyen QH, Contamin L, Nguyen TVA, Banuls AL. Insights into the processes that drive the evolution of drug resistance in Mycobacterium tuberculosis. Evol Appl. 2018; 11(9): 1498-511.
Rabha A, Singh A, Grover S, Kumari A, Pandey B, Grover A. Structural basis for isoniazid resistance in KatG double mutants of Mycobacterium tuberculosis. Microb Pathog. 2019; 129: 152-60.
Lempens P, Meehan CJ, Vandelannoote K, Fissette K, de Rijk P, Van Deun A, et al. Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Sci Rep. 2018; 8(1): 3246.
Torres JN, Paul LV, Rodwell TC, Victor TC, Amallraja AM, Elghraoui A, et al. Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. Emerg Microbes Infect. 2015; 4(7): e42.
Smaoui S, Siala M, Hadj FS, Kammoun S, Marouane C, Hachicha S, et al. Molecular characterization of Mycobacterium tuberculosis strains resistant to isoniazid. Int J Mycobacteriol. 2016; 5(Suppl 1): S151.
Sharma M, Misra RN, Gandham NR, Jadhav SV, Angadi K, Wilson V. Comparison of modified Petroff's and N-acetyl-L-cysteine-sodium hydroxide methods for sputum decontamination in tertiary care hospital in India. Medical Journal of Dr D Y Patil University. 2012; 5(2): 97-100.
Ogari CO, Nyamache AK, Nonoh J, Amukoye E. Prevalence and detection of drug resistant mutations in Mycobacterium tuberculosis among drug naive patients in Nairobi, Kenya. BMC Infect Dis. 2019; 19(1): 279.
Davis GL, Ray NA, Lahiri R, Gillis TP, Krahenbuhl JL, Williams DL, et al. Molecular assays for determining Mycobacterium leprae viability in tissues of experimentally infected mice. PLoS Negl Trop Dis. 2013; 7(8): e2404.
Schonfeld N, Bergmann T, Vesenbeckh S, Mauch H, Bettermann G, Bauer TT, et al. Minimal inhibitory concentrations of first-line drugs of multidrug-resistant tuberculosis isolates. Lung India. 2012; 29(4): 309-12.
Babamahmoodi F, Mahdavi MR, Jalali H, Talebi B, Roshan P, Mahdavi M. Evaluation of gene mutations involved in drug resistance in mycobacterium tuberculosis strains derived from tuberculosis patients in mazandaran, iran, 2013. Int J Mol Cell Med. 2014; 3(3): 190-5.
Abkar R, Zolfaghari MR, Arjomandzadegan M, Ahmadi A, Sadrnia M, Kahbazi M, et al. Minor Contribution of inhA-15 Mutations to the Rapid Detection of Isoniazid Resistance in Mycobacterium Tuberculosis Isolates. Iran J Med Sci. 2016; 41(2): 161-3.
Sechi LA, Zanetti S, Dupre I, Delogu G, Fadda G. Enterobacterial repetitive intergenic consensus sequences as molecular targets for typing of Mycobacterium tuberculosis strains. J Clin Microbiol. 1998; 36(1): 128-32.
Dinmohammadi F, Farnia P, Biglari A, Kazempoor M, Ramazanzadeh R, Masjedi MR, et al. Identification of the mutations related to resistance of mycobacterium tuberculosis to isoniazid by use of PCR-RFLP in TB patients. Sci J Kurdistan Univ Med Sci. 2010; 14(4): 1-9.
Ramaswamy SV, Reich R, Dou SJ, Jasperse L, Pan X, Wanger A, et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2003; 47(4): 1241-50.
Kambli P, Ajbani K, Sadani M, Nikam C, Shetty A, Udwadia Z, et al. Defining multidrug-resistant tuberculosis: Correlating GenoType MTBDRplus assay results with minimum inhibitory concentrations. Diagn Microbiol Infect Dis. 2015; 82(1): 49-53.
Huyen MN, Cobelens FG, Buu TN, Lan NT, Dung NH, Kremer K, et al. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother. 2013; 57(8): 3620-7.
Heym B, Saint-Joanis B, Cole ST. The molecular basis of isoniazid resistance in Mycobacterium tuberculosis. Tuber Lung Dis. 1999; 79(4): 267-71.
Sampaio JL, Viana-Niero C, de Freitas D, Hofling-Lima AL, Leao SC. Enterobacterial repetitive intergenic consensus PCR is a useful tool for typing Mycobacterium chelonae and Mycobacterium abscessus isolates. Diagn Microbiol Infect Dis. 2006; 55(2): 107-18.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Chronic Diseases Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
